regulator of calcineurin 3Genealiases: DSCR1L2 · MCIP3
Q-omics provides the consensus-scored RCAN3 profile across patient tissues and cancer cell-line models. RCAN3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RCAN3 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, RCAN3 RNA expression shows 18,369 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, BLCA, and UVM as cancer lineages where RCAN3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RCAN3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RCAN3 survival associations across molecular data types. RCAN3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RCAN3 RNA expression–survival associations across cancer types. High RCAN3 expression shows unfavorable associations in MESO, KIRP, LGG and CESC, but favorable associations in KIRC and COAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for RCAN3 RNA expression.
This table summarizes RCAN3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in BLCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RCAN3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RCAN3 shows lower tumor expression in KICH and KIRC and higher tumor expression in BLCA, LUSC, COAD and CHOL. The BLCA box plot shows higher RCAN3 RNA expression in tumor versus normal tissue (log2 FC = +1.705, t-test p < 0.001).
This table shows molecular features associated with RCAN3 in patient tissues and cancer cell lines. In patient samples, RCAN3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RCAN3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
